Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors

References

• Lanza G, Messerini L, Gafà R, et al. Colorectal tumors: the histology report. Dig Liver Dis 2011;43:S344–S55.
   PubMedGoogle Scholar
• Gao JJ, Shi ZY, Xia J, et al. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. WJG 2015;21:12059–70.
   PubMed Web of Science ®Google Scholar
• Zhang X, Raghavan S, Ihnat M, et al. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem 2014;22:3753–72.
   PubMed Web of Science ®Google Scholar
• Von Felden J, Schulze K, Gil-Ibanez I, et al. First- and second-line targeted systemic therapy in hepatocellular carcinoma—an update on patient selection and response evaluation. Diagnostics 2016;6:44.
   Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2016;0:1–9.
   Google Scholar
• Frenette C, Gish R. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. WJG 2012; 18:498–506.
   PubMed Web of Science ®Google Scholar
• Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr-Relat Cancer 2001;8:161–73.
   PubMed Web of Science ®Google Scholar
• Wu J, Ji J, Weng B, et al. Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo. Oncotarget 2014;5:4543–53.
   PubMedGoogle Scholar
• Garuti L, Roberti M, Bottegoni G. Non-ATP competitive protein kinase inhibitors. Curr Med Chem 2010;17:2804–21.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu T, Lu S, et al. Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase1 inhibitors. J Mol Model 2010;16:1195–204.
   PubMed Web of Science ®Google Scholar
• Farsangi MH. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int. J. Mol. Sci 2014;15:13768–801.
   PubMed Web of Science ®Google Scholar
• Chen Y, Fu L. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B 2011;1:197–207.
   Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol 2006; 2:358–64.
   PubMed Web of Science ®Google Scholar
• Avendaño C, Menéndez JC. Drugs that inhibit signalling pathways for tumor cell growth and proliferation. Med Chem Anticancer Drugs 2008;251–305.
   Google Scholar
• Blumenschein GR, Reckamp K, Stephenson GJ, et al. Phase Ib Study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non–small cell lung cancer. Clin Cancer Res 2010;16:279–90.
   PubMed Web of Science ®Google Scholar
• Garton AJ, Crew APA, Franklin M, et al. OSI-930: a novel selective inhibitor of kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res 2006;66:1015–24.
   PubMed Web of Science ®Google Scholar
• Yap TA, Arkenau HT, Camidge DR, et al. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res 2013;19:909–19.
   PubMed Web of Science ®Google Scholar
• Riesterer O, Matsumoto F, Wang L, et al. A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs 2011;29:514–22.
   PubMed Web of Science ®Google Scholar
• Lowinger TB, Riedl B, Dumas J, et al. Design and discovery of small molecules targeting Raf-1 kinase. Curr Pharm Des 2002;8:2269–78.
   PubMed Web of Science ®Google Scholar
• El-Aarag BYA, Kasai T, Zahran MAH, et al. In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs. Int Immunopharmacol 2014;21:283–92.
   PubMed Web of Science ®Google Scholar
• Barnes TA, O’Kane GM, Vincent MD, et al. Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer. Front Oncol 2017;7:113.
   PubMed Web of Science ®Google Scholar
• Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012;6:155–76.
   PubMed Web of Science ®Google Scholar
• Lu M, Kong X, Wang H, et al. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 2017;8:8775–84.
   PubMedGoogle Scholar
• Nerini IF, Cesca M, Bizzaro F, et al. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer 2016;35:61
   PubMed Web of Science ®Google Scholar
• Bates D, Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol 2017;83:255–68.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012;29:2943–71.
   PubMed Web of Science ®Google Scholar
• Mikstacka R, Stefański T, Różański J. Tubulin-interactive stilbene derivatives as anticancer agents. Cell Mol Biol Lett 2013;18:368–97.
   PubMed Web of Science ®Google Scholar
• Mauer AM, Cohen EE, Ma PC, et al. A Phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:631–6.
   PubMed Web of Science ®Google Scholar
• Hu MJ, Zhang B, Yang HK, et al. Design, synthesis and molecular docking studies of novel indole–pyrimidine hybrids as tubulin polymerization inhibitors. Chem Biol Drug Des 2015;86:1491–500.
   PubMed Web of Science ®Google Scholar
• Staben LR, Yu S, Chen J, et al. Stabilizing a tubulysin antibody–drug conjugate to enable activity against multidrug-resistant tumors. ACS MedChem Lett 2017;8:1037–41.
   PubMed Web of Science ®Google Scholar
• Nguyen TL, McGrath C, Hermone AR, et al. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005;48:6107–16.
   PubMed Web of Science ®Google Scholar
• Zefirova ON, Diikov AG, Zyk NV, et al. Ligands of the colchicine site of tubulin:a common pharmacophore and new structural classes. Russ Chem Bull Int Ed 2007;56:680–8.
   Web of Science ®Google Scholar
• Botta M, Forli S, Magnani M, et al. Molecular modeling approaches to study the binding mode on tubulin of microtubule destabilizing and stabilizing agents. Top Curr Chem 2009;286:279–328.
   PubMed Web of Science ®Google Scholar
• Fortin S, Bérubé G. Advances in the development of hybrid anticancer drugs. Expert Opin Drug Discov 2013;8:1029–47.
   PubMed Web of Science ®Google Scholar
• Albert JS, Blomberg N, Breeze AL, et al. An integrated approach to fragment-based lead generation:philosophy, strategy and case studies from AstraZeneca’s drug discovery programmes. Curr Top Med Chem 2007;7:1600–29.
   PubMed Web of Science ®Google Scholar
• Chekler ELP, Kiselyov AS, Ouyang X, et al. Discovery of dual VEGFR-2 and tubulin inhibitors with in vivo efficacy. ACS Med Chem Lett 2010;1:488–92.
   PubMed Web of Science ®Google Scholar
• Wilson C, Ye X, Pham T, et al. AXL inhibition sensitizes mesenchymal cancer cells to anti-mitotic drugs. Cancer Res 2014;74:5878–90.
   PubMed Web of Science ®Google Scholar
• Elshaier YAMM, Shaaban MA, Abd El Hamid MK, et al. Design and synthesis of pyrazolo[3,4-d]pyrimidines: Nitric oxide releasing compounds targeting hepatocellular carcinoma. Bioorg Med Chem 2017;25:2956–70.
   PubMed Web of Science ®Google Scholar
• Abdelhaleem EF, Abdelhameid MK, Kassab AE, et al. Design and synthesis of thienopyrimidine urea derivativeswithpotential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Eur J Med Chem 2018;143:1807–25.
   PubMed Web of Science ®Google Scholar
• Hu Y, Yang S, Shilliday FB, et al. Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome P450 enzymes. Drug MetabDispos 2010;38:1522–31.
   PubMed Web of Science ®Google Scholar
• Medower C, Wen L, Johnson WW. Cytochrome P450 oxidation of the thiophene-containing anticancer drug 3-[(quinolin-4-ylmethyl)-amino]-thiophene-2-carboxylic acid (4-trifluoromethoxy-phenyl)-amide to an electrophilic intermediate. Chem Res Toxicol 2008;21:1570–77.
   PubMed Web of Science ®Google Scholar
• Fadda AA, Bondock S, Rabie R, et al. Cyanoacetamide derivatives as sythons in heterocyclic synthesis. Turk J Chem 2008;32:259–86.
   Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–22.
   PubMed Web of Science ®Google Scholar
• El-Meligie S, Taher AT, Kamal AM, et al. Design, synthesis and cytotoxic activity of certain novel chalcone analogous compounds. Eur J Med Chem 2017;126:52–60.
   PubMed Web of Science ®Google Scholar
• Irfan M, Aneja B, Yadava U, et al. Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. Eur J Med Chem 2015;93:246–54.
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Karthikeyan E. Microwave synthesis-a potential tool for green chemistry. Int J Chemtech Res 2011;3:466–70.
   Google Scholar
• Stefanidis G and Stankiewicz AJ. Energy sources for green chemistry Alternative Energy Sources for Green Chemistry,1st ed. London:The Royal Society of Chemistry; 2016:1–3.
   Google Scholar
• Gewald K, Hain U, Schmidt M. Substituierte 3,4-diamino-thieno[2,3-b]pyrrole. J Prakt Chem 1986;328:459–64.
   Google Scholar
• Raslan MA, Sayed SM. Studies with Heterocyclic -Enaminoniriles: a simple route for the synthesis of polyfunctionally substituted thiophene, Imidazo[1,2:1,6]pyrimido[5,4-b]thiophene and Thieno[3,2-d]pyrimidine. J Chin Chem Soc 2003;50:909.
   Web of Science ®Google Scholar
• Santilli AA, Kim DH, Wanser SV. Synthesis of pyrimido[4,5-e][1,4]oxazepin-5-ones. J Heterocyclic Chem 1972;9:309–453.
   Web of Science ®Google Scholar
• Ho YW, Yao WH. Synthesis and characterization of new pyrimidine based 1,3,4-oxa(thia)diazoles, 1,2,4-triazoles and 4-thiazolidinones. Dyes and Pigments 2009;2009:281.
   Google Scholar
• Mabkhoot YN. Synthesis and chemical characterisation of new bis-thieno [2,3-b]thiophene derivatives. Molecules 2010;15:3329–27.
   PubMed Web of Science ®Google Scholar
• Tolba MF, Esmat A, Al-Abd AM, et al. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. Int Union Biochem Mol Biol 65 2013;65:716–29.
   Google Scholar
• Hassan M, Watari H, AbuAlmaaty A, et al. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014;2014:150845.
   PubMed Web of Science ®Google Scholar
• Brentnall M, Rodriguez-Menocal L, De Guevara RL, et al. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol 2013;14:32.
   PubMed Web of Science ®Google Scholar
• Roy K, Kar S, Narayan Das R. Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment. 1st ed. 2015;70–4.
   Google Scholar